MBC-11 is a first-in-class bone-targeting conjugate of a bisphosphonate ester and the antimetabolite cytarabine (araC), with potential therapeutic application in tumor-induced bone disease (TIBD); it significantly inhibits proliferation of human multiple myeloma cell lines (KAS-6/1, DP-6, KP-6) in vitro at concentrations ranging from 10⁻⁸ to 10⁻⁴ M; in vivo, MBC-11 (0.04 μg/day, s.c.) reduces the incidence of bone metastases and decreases bone tumor burden compared to PBS or zoledronate treatment, preserves bone structure, and may improve overall survival, supporting its further investigation as a treatment for TIBD.